Reuters logo
3 个月前
BRIEF-Lion Biotechnologies says first patient dosed in 2nd cohort of ln-144 phase 2 trial for metastatic melanoma
2017年5月19日 / 中午12点09分 / 3 个月前

BRIEF-Lion Biotechnologies says first patient dosed in 2nd cohort of ln-144 phase 2 trial for metastatic melanoma

May 19 (Reuters) - Lion Biotechnologies Inc:

* Lion Biotechnologies announces first patient dosed in second cohort of ln-144 phase 2 trial for metastatic melanoma

* Lion Biotechnologies -phase 2 multicenter, three-cohort study to assess safety & efficacy of ln-144 for treatment of patients with metastatic melanoma Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below